Evidence map›Paper›PMID 20054870›Full record

ArticleHepatology (Baltimore, Md.)2010

Progenitor-derived hepatocellular carcinoma model in the rat.

Jesper B Andersen, Roberto Loi, Andrea Perra, Valentina M Factor, Giovanna M Ledda-Columbano, Amedeo Columbano, Snorri S Thorgeirsson

Open access · bronzeAbstract read
In one paragraph

Article in Hepatology (Baltimore, Md.), 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 79 papers.

0numbers the graph read from it
0cells of the map it votes in
79citing papers in PubMed
5.3field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

79 citing papers in PubMed, 139 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Copy-Number Alteration Burden Differentially Impacts Immune Profiles and Molecular Features of Hepatocellular Carcinoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2020
    Article
  15. Review
  16. Review
  17. Review
  18. Article
  19. Review
  20. Review

19 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Jesper B AndersenLaboratory of Experimental Carcinogenesis, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Roberto Loi
Andrea Perra
Valentina M Factor
Giovanna M Ledda-Columbano
Amedeo Columbano
Snorri S Thorgeirsson
University of Cagliari · ITNational Cancer Institute · USZero to Three · US

Funding

Cancer stem cells and human liver cancerZIABC011031 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI THORGEIRSSON, SNORRI · 2009 to 2014
$3.7M
Comparative Functional GenomicsZIABC011170 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI THORGEIRSSON, SNORRI · 2009 to 2012
$1.4M
Intramural NIH HHS Z99 CA999999
6 · The paper itself

Abstract

unlabelledHuman hepatocellular carcinoma (HCC) is a heterogeneous disease of distinct clinical subgroups. A principal source of tumor heterogeneity may be cell type of origin, which in liver includes hepatocyte or adult stem/progenitor cells. To address this issue, we investigated the molecular mechanisms underlying the fate of the enzyme-altered preneoplastic lesions in the resistant hepatocyte (RH) model. Sixty samples classified as focal lesions, adenoma, and early and advanced HCCs were microdissected after morphological and immunohistochemical evaluation and subjected to global gene expression profiling. The analysis of progression of the persistent glutathione S-transferase (GSTP)(+) focal lesions to fully developed HCC showed that approximately 50% of persistent nodules and all HCCs expressed cytokeratin 19 (CK19), whereas 14% of remodeling nodules were CK19(+). Unsupervised hierarchical clustering of the expression profiles also grouped the samples according to CK19 expression. Furthermore, supervised analysis using the differentially expressed genes in each cluster combined with gene connectivity tools identified 1308 unique genes and a predominance of the AP-1/JUN network in the CK19(+) lesions. In contrast, the CK19-negative cluster exhibited only limited molecular changes (156 differentially expressed genes versus normal liver) consistent with remodeling toward differentiated phenotype. Finally, comparative functional genomics showed a stringent clustering of CK19(+) early lesions and advanced HCCs with human HCCs characterized by poor prognosis. Furthermore, the CK19-associated gene expression signature accurately predicted patient survival (P < 0.009) and tumor recurrence (P < 0.006).

conclusionOur data establish CK19 as a prognostic marker of early neoplastic lesions and strongly suggest the progenitor derivation of HCC in the rat RH model. The capacity of CK19-associated gene signatures to stratify HCC patients according to clinical prognosis indicates the usefulness of the RH model for studies of stem/progenitor-derived HCC.

Indexed as

AnimalsCarcinoma, HepatocellularGlutathione TransferaseImmunohistochemistryKeratin-19Liver NeoplasmsMaleMitogen-Activated Protein Kinase 14Oligonucleotide Array Sequence AnalysisPrognosisProportional Hazards ModelsRatsRats, Inbred F344Stem CellsGlutathione TransferaseKeratin-19Mitogen-Activated Protein Kinase 14

Identifiers

PMID20054870
PMCPMC2914300
OpenAlexW2016281479

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.